WHO Director-General's Opening Remarks At Member States Information Session On Mpox – 23 August 2024
Portfolio Pulse from Benzinga Newsdesk
The WHO has declared a public health emergency of international concern due to the rapid spread of a new mpox clade, clade 1b, primarily affecting the Democratic Republic of the Congo and neighboring countries. A Global Mpox Strategic Preparedness and Response Plan has been developed, requiring an estimated $135 million for the acute phase of the outbreak. WHO is coordinating international efforts to control the outbreak.
August 23, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chimerix, a biopharmaceutical company, may see increased interest due to WHO's mpox emergency declaration and the need for medical countermeasures.
Chimerix is involved in developing antiviral treatments, which may be in demand due to the mpox outbreak. WHO's declaration and response plan highlight the need for medical countermeasures, potentially benefiting companies like Chimerix.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Emergent BioSolutions, known for its vaccines and therapeutics, might see increased demand following WHO's mpox emergency declaration.
Emergent BioSolutions produces vaccines and therapeutics, which are crucial in controlling outbreaks. The WHO's emergency declaration may lead to increased demand for their products.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
GeoVax Labs, a company focused on developing vaccines, may benefit from WHO's mpox emergency declaration and the need for vaccines.
GeoVax Labs is involved in vaccine development, which is critical in the context of the mpox outbreak. WHO's declaration and response plan may increase demand for vaccines, benefiting GeoVax.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Inovio Pharmaceuticals, which develops DNA medicines, might see increased interest due to WHO's mpox emergency declaration.
Inovio Pharmaceuticals develops DNA medicines, which may be relevant in addressing the mpox outbreak. WHO's declaration and response plan could lead to increased interest in their products.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Moderna, known for its mRNA technology, may see increased demand for its vaccine capabilities following WHO's mpox emergency declaration.
Moderna's mRNA technology is pivotal in vaccine development. The WHO's emergency declaration may lead to increased demand for their vaccine capabilities.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60